BibTex RIS Cite

IGF-1 and IGFBP-3 levels in Patients with non-Hodgkin’s Lymphoma

Year 2006, Volume: 11 Issue: 2, 98 - 102, 01.04.2006

Mustafa Keleş Mehmet Gündoğdu Fuat Erdem Mehmet Türkeli Leyla Yıldız Hamdullah Turhan

Abstract

Objectives: Insulin-like growth factor 1 (IGF-1) is an important growth and anti-apoptotic factor for the cancer cells in several malignancies. IGF binding protein-3 (IGFBP-3) also apparently inhibits growth and induces apoptosis through IGF-independent mechanisms. In this study it was aimed to measure serum IGF-1 and IGFBP-3 levels in 25 patients with non-Hodgkin’s lymphoma and to compare with these results to healthy controls, and it was also aimed association between these results and some prognostic factors. Materials and Methods: Twenty five patients with non-Hodgkin’s lymphoma (NHL) whose age ranging from 18-63 (mean ± SE 40 ± 16.19) and 25 healthy volunteer whose age ranging from 18 to 63 (mean ± SE 40 ± 16.27) were obtained in Hematology and Oncology Department. Blood samples were collected and separated serums stored in –800C until study. IGF-1 ve IGFBP-3 levels were measured with immunofluorescence assay (IFA) and immunoradiometric assay (IRMA) (respectively). Results: IGF-1 level was higher in patients with NHL (mean±SE;357.88±197.45 ng/ml) than in healthy volunteer group (332.47±140.51 ng/ml), but this difference was not statistically significance (p>0.05). IGFBP-3 level was lower in patients with NHL (mean±SE; 1753.14±603.58 ng/ml) than in healthy volunteer group (1842.84±403.33 ng/ml), but this difference was not statistically significance (p>0.05). IGFBP-3 level in patients with B symptoms (1577.35±582.52 ng/ml) was significantly lower than in patients without B symptoms (2065.66±533.86 ng/ml) (p

Keywords

-

References

  • Jerome L, Shiry L, Jones BL. Deregulation of the IGF axis in cancer: epidemiological evidence and potential therapeutic interventions. Endocr Relat Cancer 2003; 10: 561-578.
  • Fürstenberger G, Senn HJ. Insulin-like growth factors and cancer. Lancet Oncol 2002; 3: 298-302.
  • Giovannucci E. Insulin-like growth factor-I and their binding protein-3 and risk of cancer. Hormone Research 1999; 51: 34-41.
  • LeRoith D, Baserga R, Helman L, Charles T. Roberts Jr. Insulin- like Growth Factors and Cancer. Ann Intern Med 1995; 122: 54- 59.
  • Grimberg A, Cohen P. Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol 2000; 183: 1-9.
  • Czech MP. Signal transmission by the IGF’s. Cell 1989; 59: 235- 238.
  • Wu X, Yu H, Amos C, Hong W, Spitz M. Joint effect of insulin- like growth factors and mutagen sensitivity in lung cancer risk. J Natl Cancer Inst 2000; 92: 737-743.
  • Harman SM, Metter EJ, Blackman MR, Landis PK, Carter HB. Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF- binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. J Clin Endocrinol Metab 2000; 85: 4258- 4265.
  • Wolk A, Mantzoros CS, Andersson SO, et al. Insulin-like growth factor I and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst 1998; 90: 911-915.
  • Aksoy Y, Aksoy H, Bakan E, Atmaca AF, Akçay F. Serum insulin-like growth factor-I and insülin-like binding protein-3 in localized, metastasized prostate cancer and benign prostatic hyperplasia. Urol Int 2004; 72: 62-65.
  • Yu H, Spitz MR, Mistry J, Gu J, Hong, WK, Wu X. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case- control analysis. J Natl Cancer Inst 1999; 91: 151-156.
  • Lukanova A, Lundin E, Toniolo P, Micheli A, Akhmedkhanov A, Rinaldi S, Muti P, Lenner P, Biessy C, Krogh V, Zeleniuch- Jacquotte A, Berrino F, Hallmans G, Riboli E, Kaaks R. Circulating levels of insulin-like growth factor-I and risk of ovarian cancer. Int J Cancer 2002; 101: 549-554.
  • Ayabe T, Tsutsumi O, Sakai H, Yoshikawa H, Yano T, Kurimoto F, Taketani Y. Increased circulating levels of insulin-like growth factor-I and decreased circulating levels of insulin-like growth factor binding protein-1 in postmenopausal women with endometrial cancer. Endocr J 1997; 44: 419-424.
  • Steller MA, Delgado CH, Bartels CJ, Woodworth CD, Zou Z. Overexpression of the insulin-like growth factor-1 receptor and autocrine stimulation in human cervical cancer cells. Cancer Res 1996; 56: 1761-1765.
  • Lee DY, Yang DH, Kang CW, Kim SJ, Joo CU, Cho SC, Kim JS. Serum Insulin-like Growth Factors (IGFs) and IGF Binding Protein (IGFBP)-3 in Patients with Gastric Cancer: IGFBP-3 protease activity induced by surgery. JKMS 1997: 12: 32-39.
  • Molica S, Vitelli G, Mirabelli R, et al. Serum insulin-like growth factor is not elevated in patients with early B-cell chronic lymphocytic leukemia but is still a prognostic factor for disease progression. Eur J Haematol 2006; 76: 51-57.
  • Çömlekçi A. Doku büyüme faktörleri ve eikozanoidler. İçinde: Kabalak T, Yılmaz C, Tüzün M (yazarlar). Endokrinoloji El Kitabı. İzmir: İzmir Güven Kitabevi, 2004: 45-59.
  • Reiter EO, Rosenfeld RG. Normal and aberant growth. In: Larsen PR, Kronenberg HM, Melmed S, Polonsky KS (eds). Williams Textbook of Endocrinology. Philadelphia: Saunders, 2003: 1016- 1031.
  • Kabul Tarihi: 18.02.2006

Non-Hodgkin Lenfomalı Hastalarda IGF-1 ve IGFBP-3 Düzeyleri

Year 2006, Volume: 11 Issue: 2, 98 - 102, 01.04.2006

Mustafa Keleş Mehmet Gündoğdu Fuat Erdem Mehmet Türkeli Leyla Yıldız Hamdullah Turhan

Abstract

Amaç: İnsülin benzeri büyüme faktörü (IGF), bir çok kanser türünde kanser hücreleri için önemli bir büyüme ve antiapopitotik faktördür. İnsülin benzeri büyüme faktörü bağlayıcı protein-3 (IGFBP-3) ise IGF-1 den bağımsız apopitozisi uyarır ve büyümeyi inhibe eder. Bu çalışmada serum IGF- 1 ve IGFBP-3 düzeylerine bakmayı, sağlıklı kontrol ile karşılaştırmayı ve bazı prognostik faktörlerle ilişkilerini araştırmayı amaçladık. Gereç ve Yöntem: Hematoloji ve Onkoloji Bilim Dallarında non Hodgkin lenfoma (NHL) tanısı konan ve yaşları 18-63 (ortalama 40±16.19) arasında olan 25 olgu ile, 18-63 yaşları arasında olan 25 sağlıklı gönüllüden 8-10 ml venöz kan alındı. Santrifüj edilen kanların serumları ayrılarak çalışma gününe kadar -800C de derin dondurucuda bekletildi. Hasta ve kontrol serumlarından IGF-1 ve IGFBP-3 ölçümleri immunoflorasan assay (IFA) ve immunoradyometrik assay (IRMA) yöntemleri ile yapıldı. Bulgular: Hasta grubunun serum IGF-I düzeyi (357.88±197.45 ng/ml) kontrol grubuna (332.47±140.51 ng/ml) göre yüksek olmasına rağmen bu fark istatistiksel olarak anlamlı değildi (p>0.05). Hasta grubunun IGFBP-3 (1753.14±603.58 ng/ml) düzeyleri kontrol grubuna (1842.84±403.33 ng/ml) göre düşük olmasına rağmen bu fark da istatistiksel olarak anlamlı değildi (p>0.05). IGFBP-3 düzeyi B semptomu olan hastalarda (1577.35±582.52 ng/ml) B semptomu olmayanlara(2065.66±533.86 ng/ml) göre daha düşük olarak bulundu (p

Keywords

NHL IGF-1 IGFBP-3 ©2006 Fırat Üniversitesi Tıp Fakültesi

References

  • Jerome L, Shiry L, Jones BL. Deregulation of the IGF axis in cancer: epidemiological evidence and potential therapeutic interventions. Endocr Relat Cancer 2003; 10: 561-578.
  • Fürstenberger G, Senn HJ. Insulin-like growth factors and cancer. Lancet Oncol 2002; 3: 298-302.
  • Giovannucci E. Insulin-like growth factor-I and their binding protein-3 and risk of cancer. Hormone Research 1999; 51: 34-41.
  • LeRoith D, Baserga R, Helman L, Charles T. Roberts Jr. Insulin- like Growth Factors and Cancer. Ann Intern Med 1995; 122: 54- 59.
  • Grimberg A, Cohen P. Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol 2000; 183: 1-9.
  • Czech MP. Signal transmission by the IGF’s. Cell 1989; 59: 235- 238.
  • Wu X, Yu H, Amos C, Hong W, Spitz M. Joint effect of insulin- like growth factors and mutagen sensitivity in lung cancer risk. J Natl Cancer Inst 2000; 92: 737-743.
  • Harman SM, Metter EJ, Blackman MR, Landis PK, Carter HB. Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF- binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. J Clin Endocrinol Metab 2000; 85: 4258- 4265.
  • Wolk A, Mantzoros CS, Andersson SO, et al. Insulin-like growth factor I and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst 1998; 90: 911-915.
  • Aksoy Y, Aksoy H, Bakan E, Atmaca AF, Akçay F. Serum insulin-like growth factor-I and insülin-like binding protein-3 in localized, metastasized prostate cancer and benign prostatic hyperplasia. Urol Int 2004; 72: 62-65.
  • Yu H, Spitz MR, Mistry J, Gu J, Hong, WK, Wu X. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case- control analysis. J Natl Cancer Inst 1999; 91: 151-156.
  • Lukanova A, Lundin E, Toniolo P, Micheli A, Akhmedkhanov A, Rinaldi S, Muti P, Lenner P, Biessy C, Krogh V, Zeleniuch- Jacquotte A, Berrino F, Hallmans G, Riboli E, Kaaks R. Circulating levels of insulin-like growth factor-I and risk of ovarian cancer. Int J Cancer 2002; 101: 549-554.
  • Ayabe T, Tsutsumi O, Sakai H, Yoshikawa H, Yano T, Kurimoto F, Taketani Y. Increased circulating levels of insulin-like growth factor-I and decreased circulating levels of insulin-like growth factor binding protein-1 in postmenopausal women with endometrial cancer. Endocr J 1997; 44: 419-424.
  • Steller MA, Delgado CH, Bartels CJ, Woodworth CD, Zou Z. Overexpression of the insulin-like growth factor-1 receptor and autocrine stimulation in human cervical cancer cells. Cancer Res 1996; 56: 1761-1765.
  • Lee DY, Yang DH, Kang CW, Kim SJ, Joo CU, Cho SC, Kim JS. Serum Insulin-like Growth Factors (IGFs) and IGF Binding Protein (IGFBP)-3 in Patients with Gastric Cancer: IGFBP-3 protease activity induced by surgery. JKMS 1997: 12: 32-39.
  • Molica S, Vitelli G, Mirabelli R, et al. Serum insulin-like growth factor is not elevated in patients with early B-cell chronic lymphocytic leukemia but is still a prognostic factor for disease progression. Eur J Haematol 2006; 76: 51-57.
  • Çömlekçi A. Doku büyüme faktörleri ve eikozanoidler. İçinde: Kabalak T, Yılmaz C, Tüzün M (yazarlar). Endokrinoloji El Kitabı. İzmir: İzmir Güven Kitabevi, 2004: 45-59.
  • Reiter EO, Rosenfeld RG. Normal and aberant growth. In: Larsen PR, Kronenberg HM, Melmed S, Polonsky KS (eds). Williams Textbook of Endocrinology. Philadelphia: Saunders, 2003: 1016- 1031.
  • Kabul Tarihi: 18.02.2006
There are 19 citations in total.

Details

Primary Language Turkish
Journal Section Articles
Authors

Mustafa Keleş This is me

Mehmet Gündoğdu This is me

Fuat Erdem This is me

Mehmet Türkeli This is me

Leyla Yıldız This is me

Hamdullah Turhan This is me

Publication Date April 1, 2006
Published in Issue Year 2006 Volume: 11 Issue: 2

Cite

APA Keleş, M., Gündoğdu, M., Erdem, F., Türkeli, M., et al. (2006). Non-Hodgkin Lenfomalı Hastalarda IGF-1 ve IGFBP-3 Düzeyleri. Fırat Tıp Dergisi, 11(2), 98-102.
AMA Keleş M, Gündoğdu M, Erdem F, Türkeli M, Yıldız L, Turhan H. Non-Hodgkin Lenfomalı Hastalarda IGF-1 ve IGFBP-3 Düzeyleri. Fırat Tıp Dergisi. April 2006;11(2):98-102.
Chicago Keleş, Mustafa, Mehmet Gündoğdu, Fuat Erdem, Mehmet Türkeli, Leyla Yıldız, and Hamdullah Turhan. “Non-Hodgkin Lenfomalı Hastalarda IGF-1 Ve IGFBP-3 Düzeyleri”. Fırat Tıp Dergisi 11, no. 2 (April 2006): 98-102.
EndNote Keleş M, Gündoğdu M, Erdem F, Türkeli M, Yıldız L, Turhan H (April 1, 2006) Non-Hodgkin Lenfomalı Hastalarda IGF-1 ve IGFBP-3 Düzeyleri. Fırat Tıp Dergisi 11 2 98–102.
IEEE M. Keleş, M. Gündoğdu, F. Erdem, M. Türkeli, L. Yıldız, and H. Turhan, “Non-Hodgkin Lenfomalı Hastalarda IGF-1 ve IGFBP-3 Düzeyleri”, Fırat Tıp Dergisi, vol. 11, no. 2, pp. 98–102, 2006.
ISNAD Keleş, Mustafa et al. “Non-Hodgkin Lenfomalı Hastalarda IGF-1 Ve IGFBP-3 Düzeyleri”. Fırat Tıp Dergisi 11/2 (April 2006), 98-102.
JAMA Keleş M, Gündoğdu M, Erdem F, Türkeli M, Yıldız L, Turhan H. Non-Hodgkin Lenfomalı Hastalarda IGF-1 ve IGFBP-3 Düzeyleri. Fırat Tıp Dergisi. 2006;11:98–102.
MLA Keleş, Mustafa et al. “Non-Hodgkin Lenfomalı Hastalarda IGF-1 Ve IGFBP-3 Düzeyleri”. Fırat Tıp Dergisi, vol. 11, no. 2, 2006, pp. 98-102.
Vancouver Keleş M, Gündoğdu M, Erdem F, Türkeli M, Yıldız L, Turhan H. Non-Hodgkin Lenfomalı Hastalarda IGF-1 ve IGFBP-3 Düzeyleri. Fırat Tıp Dergisi. 2006;11(2):98-102.